Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector
Reexamination Certificate
2007-09-25
2007-09-25
Chan, Christina (Department: 1644)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
C424S185100
Reexamination Certificate
active
10104610
ABSTRACT:
The present invention relates to cDNA encoding a soluble neuropilin protein (sNP) which is isolated from neuropilin (NP) producing cells or is recombinantly engineered from NP-encoding DNA. NP-1 and NP-2 are preferred NPs but any neuropilin or VEGF receptor (VEGFR), where the constituents share at least about 85% homology with either of the above VEGF165R/NP-1 and NP-2. More preferably, such constituent shares at least 90% homology. Still more preferably, each constituent shares at least 95% homology.
REFERENCES:
patent: 6204011 (2001-03-01), Kendall et al.
patent: WO94/11499 (1994-05-01), None
patent: WO95/33050 (1995-12-01), None
patent: WO96/40769 (1996-12-01), None
Yamada et al, Blood 97(6): 1671-8, 2001.
Bodey et al, Anticancer Research 20: 2665-2676, 2000.
Ezzell et al, Journal of NIH Research 7: 46-49, 1995.
Spitler et al, Cancer Biotherapy 10: 1-3, 1995.
Soker et al, J Biol Chem 272(50): 31582-88, Dec. 12, 1997.
Dermer et al, Bio/Technology 12: 320, 1994.
Gura et al, Science 278: 1041-1042, Nov. 1997.
T. Omura et al., “Identification of a 190 kDa Vascular Endothelial Growth Factor 165 Cell Surface Binding Protein on a Human Glioma Cell Line,” J. Biol. Chem., 272(37):23317-23322, 1997.
S. Soker et al., “Neuropilin-1 is expressed by endothelial and Tumor Cells as an Isoform-Specific Receptor for Vascular Endothelial Growth Factor,” Cell, 92:735-745, 1998.
S. Soker et al., “Characterization of Novel Vascular Endothelial Growth factor (VEGF) Receptors on Tumor Cells that Bind VEGF165 Via it Exon 7-Encoded Domain,” J. Biol. Chem., 271(10): 5761-5767, 1996.
H. Chen et al., “Neuropilin-2, A Novel Member of the Neuropilin Family, is a High Affinity receptor for the Semaphorins sema E and sema IV but not sema III,” Neuron, 19:547-559, 1997.
A. L. Kolodkin et al., “Neuropilin is a Semaphorin III Receptor,” Cell, 90:753-762, 1997.
Ngo et al., 1994, The Protein Folding Problem and Tertiary Structure Prediction, pp. 492-495.
Gagnon Michael L.
Klagsbrun Michael
Soker Shay
Chan Christina
Children's Medical Center Corporation
Huynh Phuong
Nixon & Peabody LLP
LandOfFree
Soluble inhibitors of vascular endothelial growth factor and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Soluble inhibitors of vascular endothelial growth factor and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Soluble inhibitors of vascular endothelial growth factor and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3801101